NUVATION BIO
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. Nuvation Bio was founded in 2018 by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation. Nuvation Bio has offices in New York and San Francisco.
NUVATION BIO
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.nuvationbio.com
Total Employee:
11+
Status:
Active
Total Funding:
777 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Font Awesome Domain Not Resolving Wordpress Plugins
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Kerry Wentworth Chief Regulatory Officer @ Nuvation Bio
Chief Regulatory Officer
2022-07-01
David Hung Founder, President & Chief Executive Officer @ Nuvation Bio
Founder, President & Chief Executive Officer
2019-07-01
David Liu Chief Medical Officer @ Nuvation Bio
Chief Medical Officer
2022-07-01
David Hanley Chief Technical Operations Officer @ Nuvation Bio
Chief Technical Operations Officer
2021-06-01
Jennifer Fox Chief Financial Officer @ Nuvation Bio
Chief Financial Officer
2020-10-01
Gary Hattersley Chief Scientific Officer @ Nuvation Bio
Chief Scientific Officer
2019-07-01
Founder
Stock Details
Investors List
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Nuvation Bio
683 CAPITAL
683 CAPITAL investment in Post-IPO Equity - Nuvation Bio
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Nuvation Bio
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - Nuvation Bio
OrbiMed
OrbiMed investment in Post-IPO Equity - Nuvation Bio
Irving Investors
Irving Investors investment in Post-IPO Equity - Nuvation Bio
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Post-IPO Equity - Nuvation Bio
Deerfield
Deerfield investment in Post-IPO Equity - Nuvation Bio
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Nuvation Bio
The Baupost Group
The Baupost Group investment in Post-IPO Equity - Nuvation Bio
Key Employee Changes
Official Site Inspections
http://www.nuvationbio.com Semrush global rank: 1.8 M Semrush visits lastest month: 12.68 K
- Host name: 167.88.40.145
- IP address: 167.88.40.145
- Location: Waterloo Canada
- Latitude: 43.4103
- Longitude: -80.5038
- Timezone: America/Toronto
- Postal: N2E
More informations about "Nuvation Bio"
Home - NUVATION BIO, INC.
Nov 6, 2024 · We are focused on developing and commercializing novel therapies for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies …See details»
About Us - NUVATION BIO, INC.
Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates.See details»
Management Team - NUVATION BIO, INC.
Our management team is comprised of experienced executives with long track records of success in the development of pharmaceuticals, biotechnology drugs and medical devices. Dr. Hung …See details»
Nuvation Bio Inc. - Nuvation Bio Appoints Industry Veteran …
Oct 7, 2024 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in …See details»
Nuvation Bio Inc. - Investor Relations
Oct 7, 2024 · Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product …See details»
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Apr 10, 2024 · Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025; Shareholders of Nuvation Bio and …See details»
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock …
Mar 25, 2024 · Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/. About …See details»
Nuvation Bio - LinkedIn
Nuvation Bio is focused on treating the most difficult-to-treat cancers, for which conventional therapies have failed. Nuvation Bio is a late-stage, global biopharmaceutical company tackling...See details»
Nuvation Bio - Crunchbase Company Profile & Funding
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology. It engages in treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.See details»
Nuvation Bio Company Profile 2024: Stock …
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral …See details»
Nuvation Bio Reports First Quarter 2024 Financial Results and …
NEW YORK, May 14, 2024 -- (BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by …See details»
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Apr 10, 2024 · Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025. Shareholders of Nuvation Bio and …See details»
Nuvation Bio Provides Corporate Update and Highlights Key 2022 …
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by …See details»
Nuvation Bio Inc. - Nuvation Bio Reports First Quarter 2024 …
Mar 31, 2024 · Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025.See details»
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly …
NEW YORK – February 10, 2021 – Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel …See details»
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study …
NEW YORK, June 01, 2024 -- (BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs …See details»
Working at Nuvation Bio - Glassdoor
At Nuvation Bio, we know our people are our greatest strength and we are focused on creating an environment where you can thrive. We aim to build a culture that is respectful, thoughtful and …See details»
Nuvation Bio Announces Updates and Upcoming Presentations for …
NEW YORK, July 23, 2024 -- (BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs …See details»
Nuvation Bio Inc. - Nuvation Bio Announces Updates and …
Jul 23, 2024 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs …See details»
Nuvation Bio Inc. - Nuvation Bio Reports Second Quarter 2024 …
Jun 30, 2024 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs …See details»